Treatment with Ad-shAcrp30 achieved a 76% reduction of adiponectin mRNA expression in adipose tissue (Fig. 1A) and a 35% reduction of circulating adiponectin level in the Ad-shAcrp30 group compared with the control, HF or Ad-shGFP groups (6.07±2.1 7 vs. 9.77±2.05, 9.53±2.50 and 9.14±2.87 μg/L, respectively, P<0.01, Fig. 1B). This evidence concerns the gene ADIPOQ and hydrops fetalis.